|Series A, 5/2006 |
Canadian Medical Discoveries Fund
BDC Venture Capital
Novartis Venture Fund
Viron Therapeutics is a clinical stage biopharmaceutical company pioneering the development of viral proteins to treat and prevent human inflammatory disorders. Viral proteins represent a revolutionary new class of drugs. By harnessing the evolutionary power of viruses and other pathogens to evade the human body’s protective inflammatory response, Viron is able to identify and develop powerful protein therapeutics that have distinct advantages in potency and efficacy over conventional drug therapy. Viron is the first company to successfully advance a viral protein drug into human testing.